OPK
BEARISH
$1.18
Live
OPKO Health, Inc. · NASDAQ
Target $3.4
(+188.1%)
$1.1
52W Range
$1.6
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 16, 2026
Market cap
$905.89M
P/E
N/A
ROE
-17.1%
Profit margin
-37.2%
Debt/Equity
0.31
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
OPK exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating critical failures in profitability and operational efficiency. While the company maintains a strong liquidity position with a current ratio of 3.97 and low debt, these are offset by a -19.2% decline in year-over-year revenue and deeply negative profit margins. The stock is trading below its book value (P/B 0.71), but the persistent long-term price decay (-72.8% over 5 years) suggests a value trap rather than a bargain. Despite optimistic analyst price targets, the deterministic data points to a company in structural decline.
Key Strengths
Strong short-term liquidity (Current Ratio 3.97)
Low leverage (Debt/Equity 0.31)
Trading at a discount to book value (P/B 0.71)
Consistent history of beating low earnings estimates
Positive analyst sentiment with a high target price ($3.40)
Key Risks
Severe operational weakness (Piotroski F-Score 1/9)
Significant revenue contraction (-19.2% YoY)
Deeply negative profit margins (-37.19%)
Long-term bearish price trend (-72.8% 5-year change)
Lack of positive earnings growth (YoY EPS Growth -500%)
AI Fair Value Estimate
Based on comprehensive analysis
$1.35
+14.4% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
18
Weak
45
15
10
20
0
AI Verdict
High Risk / Speculative
Key drivers: Piotroski F-Score 1/9, Negative Revenue Growth, Negative Profitability, Strong Liquidity
Confidence
90%
Value
45/100
Ref P/E, PEG, Graham Number
Positives
- P/B ratio of 0.71 suggests the stock is undervalued relative to assets
Watchpoints
- Negative Forward P/E
- Lack of earnings to support a Graham Number
Future
15/100
Ref Growth rates
Positives
- Analyst target price suggests 180% upside
Watchpoints
- Revenue growth is negative both YoY and Q/Q
- EPS growth is crashing
Past
10/100
Ref Historical trends
Positives
- Recent quarters have beaten estimates
Watchpoints
- 5-year price performance is -72.8%
- Consistent failure to achieve positive net income
Health
20/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Low Debt/Equity ratio
- High Quick Ratio (3.21)
Watchpoints
- Piotroski F-Score of 1/9 is a major red flag for financial health
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$1.18
Analyst Target
$3.4
Upside/Downside
+188.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for OPK and closest competitors.
Updated 2026-04-15
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
OPK
OPKO Health, Inc.
Primary
|
-72.8% | -20.8% | -18.1% | -22.4% | -0.8% | -0.8% |
|
FTRE
Fortrea Holdings Inc.
Peer
|
-68.8% | -68.8% | +45.4% | -12.7% | +4.8% | -0.7% |
|
ABUS
Arbutus Biopharma Corporation
Peer
|
+34.8% | +48.0% | +34.4% | +0.9% | +3.2% | +6.6% |
|
QDEL
QuidelOrtho Corporation
Peer
|
-89.6% | -86.0% | -49.5% | -54.8% | -25.4% | -8.2% |
|
INMD
InMode Ltd.
Peer
|
-67.3% | -61.5% | -4.0% | -11.4% | +3.0% | -1.9% |
OPK
OPKO Health, Inc.
Primary
5Y
-72.8%
3Y
-20.8%
1Y
-18.1%
6M
-22.4%
1M
-0.8%
1W
-0.8%
FTR
Fortrea Holdings Inc.
Peer
5Y
-68.8%
3Y
-68.8%
1Y
+45.4%
6M
-12.7%
1M
+4.8%
1W
-0.7%
ABU
Arbutus Biopharma Corporation
Peer
5Y
+34.8%
3Y
+48.0%
1Y
+34.4%
6M
+0.9%
1M
+3.2%
1W
+6.6%
QDE
QuidelOrtho Corporation
Peer
5Y
-89.6%
3Y
-86.0%
1Y
-49.5%
6M
-54.8%
1M
-25.4%
1W
-8.2%
INM
InMode Ltd.
Peer
5Y
-67.3%
3Y
-61.5%
1Y
-4.0%
6M
-11.4%
1M
+3.0%
1W
-1.9%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-3.58
PEG Ratio
N/A
P/B Ratio
0.71
P/S Ratio
1.49
EV/Revenue
1.53
EV/EBITDA
-7.29
Market Cap
$905.89M
Profitability
Profit margins and return metrics
Profit Margin
-37.19%
Operating Margin
-28.98%
Gross Margin
13.5%
ROE
-17.14%
ROA
-6.62%
Growth
Revenue and earnings growth rates
Revenue Growth
-19.2%
Earnings Growth
N/A
Q/Q Revenue Growth
-19.16%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.31
Low debt
Current Ratio
3.97
Strong
Quick Ratio
3.21
Excellent
Cash/Share
$0.48
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
43.1%
Op. Margin
-25.8%
Net Margin
-21.1%
Total Assets
$1.9B
Liabilities
$0.7B
Equity
$1.3B
Debt/Equity
0.52x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
110%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-02-26
$-0.04
+48.9% surprise
2025-10-29
$0.03
+166.7% surprise
2025-07-31
$-0.08
+17.9% surprise
Healthcare Sector Comparison
Comparing OPK against 421 companies in the Healthcare sector
(25 bullish, 134 neutral, 262 bearish)
Return on Equity (ROE)
-17.14%
This Stock
vs
-100.15%
Sector Avg
-82.9%
(Below Avg)
Profit Margin
-37.19%
This Stock
vs
-13.63%
Sector Avg
+172.9%
(Superior)
Debt to Equity
0.31
This Stock
vs
3.22
Sector Avg
-90.3%
(Less Debt)
Revenue Growth
-19.2%
This Stock
vs
121.05%
Sector Avg
-115.9%
(Slower)
Current Ratio
3.97
This Stock
vs
4.55
Sector Avg
-12.8%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
OPK
OPKO Health, Inc.
|
BEARISH | $905.89M | - | -17.1% | -37.2% | $1.18 | |
|
FTRE
Fortrea Holdings Inc.
|
BEARISH | $877.03M | - | -102.4% | -36.2% | $9.38 | Compare |
|
ABUS
Arbutus Biopharma Corporation
|
BEARISH | $872.03M | - | -38.5% | -237.9% | $4.53 | Compare |
|
QDEL
QuidelOrtho Corporation
|
BEARISH | $865.32M | - | -46.1% | -41.5% | $12.71 | Compare |
|
INMD
InMode Ltd.
|
NEUTRAL | $857.24M | 9.46 | 13.5% | 25.3% | $13.53 | Compare |
OPK
OPKO Health, Inc.
BEARISH
Mkt Cap
$906M
P/E
-
ROE
-17.1%
Price
$1.18
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-20 | PAGANELLI JOHN A | Director | Purchase | 10,000 | $11,350 |
| 2025-11-21 | FROST PHILLIP MD ET AL | Chief Executive Officer | Purchase | 580,000 | $768,807 |
| 2025-11-20 | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | Purchase | 580,000 | $771,328 |
| 2025-11-19 | FROST PHILLIP MD ET AL | Chief Executive Officer | Purchase | 580,000 | $759,115 |
| 2025-11-18 | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | Stock Award | 46,700 | $58,842 |
| 2025-11-18 | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | Purchase | 533,300 | $678,906 |
| 2025-10-31 | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | Purchase | 150,000 | $213,435 |
PAGANELLI JOHN A
Director
2026-03-20
10,000 shares
·
$11,350
FROST PHILLIP MD ET AL
Chief Executive Officer
2025-11-21
580,000 shares
·
$768,807
FROST PHILLIP MD ET AL
Beneficial Owner of more than 10% of a Class of Security
2025-11-20
580,000 shares
·
$771,328
FROST PHILLIP MD ET AL
Chief Executive Officer
2025-11-19
580,000 shares
·
$759,115
FROST PHILLIP MD ET AL
Beneficial Owner of more than 10% of a Class of Security
2025-11-18
46,700 shares
·
$58,842
FROST PHILLIP MD ET AL
Beneficial Owner of more than 10% of a Class of Security
2025-11-18
533,300 shares
·
$678,906
FROST PHILLIP MD ET AL
Beneficial Owner of more than 10% of a Class of Security
2025-10-31
150,000 shares
·
$213,435
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
6 analysts
Barrington Research
2026-03-02
Outperform
Outperform
JP Morgan
2025-11-20
Neutral
Jefferies
2025-10-31
Buy
Hold
Barrington Research
2025-10-30
Outperform
Outperform
Past News Coverage
Recent headlines mentioning OPK from our newsroom.
Newest → oldest
No matching news yet.